[Hand-foot syndrome with capecitabine therapy].
A 72-year-old patient with esophageal carcinoma developed a severe hand-foot syndrome during second-line therapy with the oral fluoropyrimidine capecitabine. We also summarize the current knowledge with regard to the hand-foot syndrome and distinguish it from palmoplantar erythrodysesthesia.
Marini
A
A
Hautklinik der Heinrich-Heine-Universität, Moorenstrasse 5, 40225 Düsseldorf.
Hengge
U R
UR
D000284:Administration, Oral; D000964:Antimetabolites, Antineoplastic / Q000009:adverse effects* / Q000627:therapeutic use; D000069287:Capecitabine; D003841:Deoxycytidine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D004938:Esophageal Neoplasms / Q000188:drug therapy; D005472:Fluorouracil / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D005533:Foot Dermatoses / Q000139:chemically induced* / Q000175:diagnosis*; D006229:Hand Dermatoses / Q000139:chemically induced* / Q000175:diagnosis*; D006801:Humans; D008297:Male; D008875:Middle Aged; D012594:Scleroderma, Localized / Q000139:chemically induced* / Q000175:diagnosis*; D013577:Syndrome
D000964:Antimetabolites, Antineoplastic; D003841:Deoxycytidine; D000069287:Capecitabine; D005472:Fluorouracil